Faculty
Dr. Wayne Guida
Professor
Contact
Office: CHE 205E
Phone: 813-974-4129
Lab: IDRB 214
Email: wguida@usf.edu
Group Website:
Education
B.A., 91tvӰԺ
Ph.D., 91tvӰԺ
Postdoctoral Associate, Duke University
Sr. Postdoctoral Associate, Columbia University
Research
Dr. Wayne C. Guida is Professor in the Department of Chemistry, University of South Florida in Tampa and Professor in the Drug Discovery Program at the H. Lee Moffitt Cancer Center & Research Institute at the 91tvӰԺ.He is the author or co-author of over 80 research publications, holds 9 patents, and has been PI/Co-PI on over 10 research contracts/grants.Research from the Guida lab has been cited more than 8,000 times.
Prior to coming to 91tvӰԺ/Moffitt, Dr. Guida served as President and CEO of Schrödinger, Inc. and continues to serve on the company’s Scientific Advisory Board.Prior to his role as CEO of Schrödinger, he was Executive Director of Biomolecular Structure, Lead Finding, and Computing at the Novartis Institute for Biomedical Research (formerly CIBA-Geigy Pharmaceuticals) in Summit, New Jersey, where he supervised a group of scientists engaged in molecular modeling, structural bioinformatics, X-ray crystallography, protein NMR spectroscopy, protein biochemistry, and high-throughput screening.His work at CIBA-Geigy, along with collaborators at the University of Alabama at Birmingham, Southern Research Institute and BioCryst Pharmaceuticals, resulted in one of the first successful examples of the use of Structure-Based Drug Design in drug discovery.That work led to the development of clinically tested inhibitors of purine nucleoside phosphorylase.Prior to joining CIBA-Geigy, Dr. Guida was one of the original developers of the MacroModel program at Columbia University.
Dr. Guida’s main research interests include the design of inhibitors of enzymes in signal transduction pathways and the biosynthetic pathways of polyamines and lipids.These inhibitors have potential utility as drugs for the treatment of cancer and infectious diseases.The discovery, design and synthesis of non-covalent, copper-based 20S proteasome inhibitors for the treatment of cancer is also an area of significant interest to Dr. Guida’s group.